ALK-Lymphoma Analyte Control contains two cell lines that demonstrate positive and negative expression of NPM-ALK associated lymphoma. Ideal for use as a same slide control in IHC to demonstrate the reagents have been correctly applied to the slide.

The ALK translocation event was first identified in anaplastic large cell lymphomas (ALCL) and in this instance it is with the nucleophosmin (NPM) gene. The NPM-ALK fusion protein is readily detected with the use of anti-ALK antibodies such as ALK1, 4A5 and D5F3 clones available on the market. The relative expression of NPM-ALK is considerably higher than that of other ALK fusion proteins such as EML4-ALK associated with non-small cell lung cancer. These antibodies are able to be used across a variety of ALK fusion proteins by virtue of recognizing the conserved C-terminal domain of the protein, which is the common fusion partner. Due to the relatively higher expression of NPM-ALK these antibodies are generally used at higher dilutions when compared to the working dilution of the same antibodies for EML4-ALK.